Heartsciences Inc. (HSCSW) — SEC Filings
Heartsciences Inc. (HSCSW) — 46 SEC filings. Latest: 8-K (Dec 16, 2025). Includes 32 8-K, 5 10-Q, 2 10-K.
View Heartsciences Inc. on SEC EDGAR
Overview
Heartsciences Inc. (HSCSW) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 16, 2025: HeartSciences Inc. filed an 8-K on December 16, 2025, reporting a material definitive agreement and financial statements. The company, formerly Heart Test Laboratories, Inc., is incorporated in Texas and operates in the orthopedic, prosthetic & surgical appliances & supplies industry.
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 38 neutral, 1 mixed. The dominant filing sentiment for Heartsciences Inc. is neutral.
Filing Type Overview
Heartsciences Inc. (HSCSW) has filed 32 8-K, 5 10-Q, 2 10-K, 2 8-K/A, 1 S-1/A, 2 DEFA14A, 1 DEF 14A, 1 S-1 with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of HSCSW's 41 recent filings, 6 were flagged as high-risk, 20 as medium-risk, and 15 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,900 |
| Net Income | -$2,054,994 |
| EPS | -$1.58 |
| Debt-to-Equity | N/A |
| Cash Position | $2,792,231 |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- John Q. Adams
- Danielle Watson
Industry Context
The cardiac monitoring market is characterized by technological advancements and increasing demand for remote patient monitoring solutions. Companies are focusing on developing more accurate, portable, and user-friendly devices. Key players compete on features, data analytics capabilities, regulatory approvals, and reimbursement strategies. HeartSciences aims to differentiate with its MyoVista wav ECG device and cloud platform.
Top Tags
corporate-governance (10) · filing (8) · material-agreement (6) · financials (6) · delisting (5) · 8-K (5) · sec-filing (5) · corporate-action (4) · warrants (4) · 10-Q (4)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| SEC File Number | 001-41422 | Identifies the company's filing with the SEC. |
| IRS Employer Identification No. | 26-1344466 | Company's tax identification number. |
| Commission File Number | 001-41422 | Identifies the company's SEC filing history. |
| Net Loss | $2.05M | Slight increase from $2.05M in prior year, indicating continued unprofitability. |
| Revenue | $1,900 | First reported revenue, up from zero, but still negligible. |
| Cash and Cash Equivalents | $2.79M | Significant increase from $1.10M at April 30, 2025, due to financing activities. |
| Accumulated Deficit | $78.2M | Increased from $76.1M, highlighting ongoing losses and 'going concern' risk. |
| Proceeds from Series D Offering | $3.80M | Key financing activity providing liquidity for operations. |
| Reverse Stock Split Ratio | 1-for-100 | Implemented May 17, 2024, to adjust share structure. |
| Research and Development Expenses | $997,206 | Decreased from $1,224,931, showing a reduction in R&D spend. |
| Series D Units Issued | 1,317,689 | Number of units issued in the recent offering. |
| Net Loss Per Share | $1.58 | Basic and diluted net loss per share for the quarter. |
| Common Stock Outstanding | 2,647,712 | Shares outstanding as of September 10, 2025. |
| Note Payable | $1.0M | from Front Range Ventures LLC, a source of financing |
| Common Stock Warrants | 1,000,000 | issued to the School of Medicine at Mount Sinai in November 2023 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Heartsciences Inc. (HSCSW)?
Heartsciences Inc. has 46 recent SEC filings from Jan 2024 to Dec 2025, including 32 8-K, 5 10-Q, 2 10-K. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of HSCSW filings?
Across 46 filings, the sentiment breakdown is: 1 bullish, 6 bearish, 38 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Heartsciences Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Heartsciences Inc. (HSCSW) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Heartsciences Inc.?
Key financial highlights from Heartsciences Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for HSCSW?
The investment thesis for HSCSW includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Heartsciences Inc.?
Key executives identified across Heartsciences Inc.'s filings include John Q. Adams, Danielle Watson.
What are the main risk factors for Heartsciences Inc. stock?
Of HSCSW's 41 assessed filings, 6 were flagged high-risk, 20 medium-risk, and 15 low-risk.
What are recent predictions and forward guidance from Heartsciences Inc.?
Forward guidance and predictions for Heartsciences Inc. are extracted from SEC filings as they are enriched.